Growing Outsourcing of Preclinical Studies by Pharmaceutical Companies
First written in FY2017-Q1. 20 of 24 entries say "Restated". Latest entry: FY2026-H1.
2 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The company reaffirmed its view of the market environment that outsourcing by pharmaceutical companies, particularly for preclinical trials, was on an upward trend. - FY2024-Q3RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The company reaffirmed the expansion of outsourcing by pharmaceutical companies to CROs and other providers, particularly for preclinical trials, as a market trend. - FY2024-Q2RestatedAnnual report
「With remote work becoming more widespread, outsourcing by pharmaceutical companies has increased further even in preclinical trials, the area targeted by the company.」
The company reaffirmed its view of the market environment that outsourcing by pharmaceutical companies, including preclinical trials, had increased further, also against the backdrop of the expansion of remote work. - FY2023RestatedAnnual report
「Against this backdrop, more pharmaceutical companies are outsourcing development operations, including clinical trials, to external CROs (contract research organisations) to conduct new drug development rapidly and efficiently. With remote work also becoming more widespread, outsourcing by pharmaceutical companies has increased further even in preclinical trials, the area targeted by the company.」
The company reaffirmed the expansion of outsourcing by pharmaceutical companies to CROs and other providers, particularly for preclinical trials. - FY2023-Q3RestatedAnnual report
「In addition, the spread of remote work as a result of the COVID-19 pandemic has led to a further increase in outsourcing by pharmaceutical companies.」
The company reaffirmed its view of the market environment that outsourcing by pharmaceutical companies to CROs and other providers had increased further as remote work became more widespread. - FY2023-Q2RestatedAnnual report
「In addition, the spread of remote work as a result of the COVID-19 pandemic has led to a further increase in outsourcing by pharmaceutical companies.」
The company reaffirmed its view of the market environment that outsourcing by pharmaceutical companies to CROs and other providers had increased further as remote work became more widespread. - FY2023-Q1RestatedAnnual report
「In addition, the spread of remote work as a result of the COVID-19 pandemic has led to a further increase in outsourcing by pharmaceutical companies.」
The company reaffirmed its view of the market environment that outsourcing by pharmaceutical companies to CROs and other providers had increased further as remote work became more widespread. - FY2022-Q1Further increase in outsourcing associated with remote workAnnual report
「In addition, the spread of remote work as a result of the COVID-19 pandemic has led to a further increase in outsourcing by pharmaceutical companies.」
The company explained that outsourcing by pharmaceutical companies, including preclinical trials, had increased further as remote work became more widespread. - FY2021Increased outsourcing and postponement or cancellation of development projectsAnnual report
「Outsourcing has increased further among pharmaceutical companies unable to use their own facilities due to the global spread of COVID-19, while some development projects have also been postponed or cancelled.」
The company noted that outsourcing to CROs and other providers continued to expand, while development projects were also postponed or cancelled due to COVID-19. - FY2021-Q2Delays and changes to development activities due to COVID-19Annual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group. However, the COVID-19 pandemic has caused delays and changes in development activities.」
The company reaffirmed its expansion of outsourcing to CROs, including preclinical trials, while noting that COVID-19 had caused delays and changes in development operations. - FY2021-Q1RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2020RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2020-Q3RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2020-Q2RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2019RestatedAnnual report
「Against this backdrop, pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2019-Q3RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Company.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2018RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2018-Q3RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2018-Q2RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2018-Q1RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is reconfirmed as part of the market environment. - FY2017RestatedAnnual report
「Pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, including for preclinical studies, is disclosed again as part of the market environment. - FY2017-Q3RestatedAnnual report
「Against this backdrop, pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The increased use of CROs by pharmaceutical companies, particularly the expansion of outsourcing for preclinical studies, is disclosed again. - FY2017-Q2RestatedAnnual report
「Against this backdrop, pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The expansion of pharmaceutical companies' outsourcing to CROs, particularly for preclinical studies, is disclosed again. - FY2017-Q1First statedAnnual report
「Against this backdrop, pharmaceutical companies are increasingly outsourcing development activities, including clinical trials, to external CROs (contract research organizations) in order to conduct new drug development rapidly and efficiently. Outsourcing by pharmaceutical companies is also expanding in the preclinical studies targeted by the Group.」
The market environment is characterized by increased use of CROs by pharmaceutical companies, with outsourcing also trending upward in the preclinical studies targeted by the Company.